RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
Stocks · News reference
Xenon Pharmaceuticals To Present 6 Azetukalner Data Sets, Including Encore Oral Presentation Of Topline Phase 3 X-TOLE2 Results At European Epilepsy Congress, Taking Place September 5-9, 2026
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Xenon Pharmaceuticals Inc. (XENE)
Filed: 2026-08-06 AccNo: 0001193125-26-338019 Size: 464 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of $(1.07) per share